Literature DB >> 16868937

Outcomes and charges of elderly patients with acute myeloid leukemia.

Laura M Katz1, Jamie B Howell, John J Doyle, Lee S Stern, Lisa C Rosenblatt, Catherine Tak Piech, Marya D Zilberberg.   

Abstract

A retrospective database analysis was conducted to evaluate hospitalization outcomes and charges among elderly acute myeloid leukemia (AML) patients. The data source was a longitudinal (2000-2003) inpatient database from 28 US hospitals. Data on 275 AML patients aged 60 and older were analyzed for demographic and treatment characteristics, hospital mortality, length of stay (LOS), overall days of stay (DOS), and charges across multiple admissions. Multivariate modeling was performed to determine factors that influenced outcomes. Overall, 115 (41.8%) patients received inpatient chemotherapy (CT); most (90.4%) received it on the first admission. Of all initial CT regimens 40.9% consisted of a single agent. The mean LOS for initial hospitalization was 23.0 (SD 21.8) days for patients who received CT and 6.7 (SD 7.5) days for those who did not. One quarter (25.3%) of initial hospitalizations resulted in death. On initial hospitalization, mean total charges were $113,118 (SD $220,417) for patients who received CT and $43,999 (SD $190,533) for those who did not; for both groups mean charges were higher than respective subsequent admission charges. Overall, in-hospital mortality did not differ significantly between on-CT and off-CT groups (43.5 and 38.8%, respectively). In multivariate modeling, CT was significantly associated (P < 0.0001) with increased charges and LOS. Elderly patients with AML incurred substantial hospital charges and inpatient mortality. The highest charges and a substantial number of deaths occurred during first admission. Although treatment with CT was associated with increased charges and days in-hospital, inpatient mortality in the two groups was found to be similar. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868937     DOI: 10.1002/ajh.20683

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

Review 1.  A systematic review on the use of exercise interventions for individuals with myeloid leukemia.

Authors:  Jenna Smith-Turchyn; Julie Richardson
Journal:  Support Care Cancer       Date:  2015-05-07       Impact factor: 3.603

2.  High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.

Authors:  Bin-Tao Huang; Qing-Chun Zeng; Jessica Yu; Xiao-Li Liu; Zhen Xiao; Hong-Qian Zhu
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

3.  Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.

Authors:  Roland B Walter; Stephanie J Lee; Kelda M Gardner; Xiaoyu Chai; Kathleen Shannon-Dorcy; Frederick R Appelbaum; Elihu H Estey
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

Review 4.  Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia.

Authors:  Roland B Walter; Lenise R Taylor; Kelda M Gardner; Kathleen Shannon Dorcy; Jennifer E Vaughn; Elihu H Estey
Journal:  Clin Adv Hematol Oncol       Date:  2013

5.  Risk factors for length of stay and charge per day differ between older and younger hospitalized patients with AML.

Authors:  Anita J Kumar; Tobi Henzer; Angie Mae Rodday; Susan K Parsons
Journal:  Cancer Med       Date:  2018-04-16       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.